Cardiomyopathy Clinical Trials

Find Cardiomyopathy Clinical Trials Near You

Multicentre Hypertrophic Cardiomyopathy Registry

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Hypertrophic cardiomyopathy (HCM) is the most common inherited heart condition, affecting approximately 1 in 500 people. It causes the heart muscle to thicken, which can lead to blockages in blood flow (left ventricular outflow tract obstruction), shortness of breath, and an increased risk of heart failure or sudden cardiac arrest. While standard treatments exist and new targeted medications (cardiac myosin inhibitors) have recently been approved, doctors still need better data to predict which treatments will work best for each individual patient. This national registry based in the UK is a secure database that collects health information from HCM patients across multiple NHS hospital sites in the UK over several years. Participants in this study will have their routine health information collected from their medical records, including details from heart scans (echocardiograms and MRIs), blood tests, and genetic information. With this HCM registry, we aim to improve disease understanding and risk prediction, paving the way for more personalised treatment plans for the HCM community in the future

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 99
Healthy Volunteers: f
View:

• Confirmed diagnosis of Hypertrophic Cardiomyopathy (HCM) clinically and not solely explained by abnormal loading conditions (e.g., significant hypertension, valvular disease

Locations
Other Locations
United Kingdom
University of Manchester
RECRUITING
Manchester
Time Frame
Start Date: 2026-04-01
Estimated Completion Date: 2029-01-01
Participants
Target number of participants: 2500
Sponsors
Leads: University of Manchester

This content was sourced from clinicaltrials.gov